These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 11093600)
1. CPH 82 (Reumacon) in refractory inflammatory arthritis. Gudmundsdóttir ES; Jónsson H Scand J Rheumatol; 2000; 29(5):323-5. PubMed ID: 11093600 [TBL] [Abstract][Full Text] [Related]
2. CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA. Bjørneboe O; Moen F; Nygaard H; Haavik TK; Svensson B Scand J Rheumatol; 1998; 27(1):26-31. PubMed ID: 9506874 [TBL] [Abstract][Full Text] [Related]
3. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis. Lerndal T; Svensson B Rheumatology (Oxford); 2000 Mar; 39(3):316-20. PubMed ID: 10788542 [TBL] [Abstract][Full Text] [Related]
5. Difference in pharmacological activity between CPH 82 and podophyllotoxin. Rosén B Scand J Rheumatol; 1998; 27(2):159. PubMed ID: 9572647 [No Abstract] [Full Text] [Related]
6. Glucocorticoid-like anti-inflammatory versus immunosuppressive effects of CPH 82 as a single drug therapy of moderately active rheumatoid arthritis patients. Masi AT; Chatterton RT Scand J Rheumatol; 2000; 29(2):85-8. PubMed ID: 10777120 [No Abstract] [Full Text] [Related]
7. Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon) in patients with rheumatoid arthritis. Carlström K; Hedin PJ; Jönsson L; Lerndal T; Lien J; Weitoft T; Axelson M Scand J Rheumatol; 2000; 29(2):89-94. PubMed ID: 10777121 [TBL] [Abstract][Full Text] [Related]
8. Effect of CPH82 in rheumatoid arthritis. Accumulation of bone marrow cells in mitosis and clinical response. Rantapää-Dahlqvist S; Löfvenbert E; Norberg B Clin Rheumatol; 1993 Dec; 12(4):541-2. PubMed ID: 8124923 [No Abstract] [Full Text] [Related]
9. Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis. Svensson B; Pettersson H Scand J Rheumatol; 2003; 32(2):83-8. PubMed ID: 12737326 [TBL] [Abstract][Full Text] [Related]
10. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739 [TBL] [Abstract][Full Text] [Related]
11. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Suissa S; Ernst P; Hudson M; Bitton A; Kezouh A Am J Med; 2004 Jul; 117(2):87-92. PubMed ID: 15234643 [TBL] [Abstract][Full Text] [Related]